Original Research

Artificial Intelligence vs Medical Providers in the Dermoscopic Diagnosis of Melanoma

Author and Disclosure Information

 

References

This application’s current visual question-answering system is trained on a diverse set of data that includes more than 20 years of clinical encounters and user-uploaded cases submitted by more than 150,000 patients and 10,000 clinicians in more than 150 countries. All crowdsourced images used for training the dermoscopy classifier are biopsy-verified images contributed by dermatologists. These data are made up of case photographs that are tagged with metadata around the patient’s age, sex, symptoms, and diagnoses. The CNN algorithm used covers 133 skin disease classes, representing 588 clinical conditions. It also can automatically detect 7 malignant, premalignant, and benign dermoscopic categories, which is the focus of this study (Table 2). Diagnoses are verified by patient response to treatment, biopsy results, and dermatologist consensus.

Dermoscopic Disease Categories Supported by an Artificial Intelligence Application

In addition to having improved performance, supporting more than 130 disease classes, and having a diverse data set, the application used has beat competing technologies.20,24 The application currently is available on the internet in more than 30 countries after it received Health Canada Class I medical device approval and the CE mark in Europe.

Can AI Reliably Detect Melanoma?—In our study, of the lesions labeled benign, the higher PPV and NPV of the AI algorithm means that the lesions were more reliably true benign lesions, and the lesions labeled as malignant were more likely to be true malignant lesions. Therefore, the diagnosis given by the AI compared with the medical provider was significantly more likely to be correct. These findings demonstrate that this AI application can reliably detect malignant melanoma using dermoscopic images. However, this study was limited by the small sample size of medical providers. Further studies are necessary to assess whether the high diagnostic accuracy of the application translates to expedited referrals and a decrease in unnecessary biopsies.

Dermoscopy Training—This study looked at dermoscopic images instead of gross examination, as is often done in clinic, which draws into question the dermoscopic training dermatologists receive. The diagnostic accuracy using dermoscopic images has been shown to be higher than evaluation with the naked eye.5,6 However, there currently is no standard for dermoscopic training in dermatology residencies, and education varies widely.25 These data suggest that there may be a lack of dermoscopic training among dermatologists, which could accentuate the difference in performance between dermatologists and AI. Most primary care providers also lack formal dermoscopy training. Although dermoscopy has been shown to increase the diagnostic efficacy of primary care providers, this increase does not become apparent until the medical provider has had years of formal training in addition to clinical experience, which is not commonly provided in the medical training that primary care providers receive.8,26

Conclusion

It is anticipated that AI will shape the future of medicine and become incorporated into daily practice.27 Artificial intelligence will not replace physicians but rather assist clinicians and help to streamline medical care. Clinicians will take on the role of interpreting AI output and integrate it into patient care. With this advancement, it is important to highlight that for AI to improve the quality, efficiency, and accessibility of health care, clinicians must be equipped with the right training.27-29

Pages

Recommended Reading

Hair Repigmentation as a Melanoma Warning Sign
MDedge Dermatology
Symmetric Palmoplantar Papules With a Keratotic Border
MDedge Dermatology
Study highlights potential skin cancer risk of UV nail polish dryers
MDedge Dermatology
What happens to melanocytic nevi during laser hair removal?
MDedge Dermatology
Study suggests narrow excision margins safe in early melanoma resection
MDedge Dermatology
Pembrolizumab monotherapy effective for rare melanoma
MDedge Dermatology
USPSTF releases updated recommendations on skin cancer screening
MDedge Dermatology
Acute Onset of Vitiligolike Depigmentation After Nivolumab Therapy for Systemic Melanoma
MDedge Dermatology
‘Exciting’ results for cancer vaccine plus pembro in melanoma
MDedge Dermatology
Guidelines for assessing cancer risk may need updating
MDedge Dermatology